Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4650-0.0386 (-7.66%)
At close: 04:00PM EST
0.4600 -0.00 (-1.08%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5036
Open0.4973
Bid0.4550 x 3200
Ask0.4650 x 800
Day's Range0.4411 - 0.4973
52 Week Range0.4200 - 2.0000
Volume899,569
Avg. Volume700,637
Market Cap15.933M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.3180
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

    CAMBRIDGE, Mass., January 06, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli’s presentation will provide an overview of the company and will also highlight

  • Business Wire

    InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

    CAMBRIDGE, Mass., September 09, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format.

  • Business Wire

    InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

    CAMBRIDGE, Mass., September 08, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designe

Advertisement
Advertisement